Citigroup Inc. Has $74,000 Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Citigroup Inc. cut its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report) by 48.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,150 shares of the company’s stock after selling 3,913 shares during the period. Citigroup Inc.’s holdings in Tarsus Pharmaceuticals were worth $74,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Royal Bank of Canada boosted its stake in shares of Tarsus Pharmaceuticals by 122.0% in the 2nd quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock worth $50,000 after buying an additional 1,548 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Tarsus Pharmaceuticals by 310.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,736 shares of the company’s stock worth $66,000 after buying an additional 2,825 shares during the last quarter. UBS Group AG raised its holdings in shares of Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock worth $71,000 after purchasing an additional 1,142 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tarsus Pharmaceuticals by 65.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after purchasing an additional 2,092 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $94,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Barclays lifted their price target on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. Lifesci Capital restated an “outperform” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, December 26th. Oppenheimer restated an “outperform” rating and set a $59.00 price target (up from $55.00) on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 28th. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, HC Wainwright upped their price target on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.38.

Get Our Latest Stock Analysis on TARS

Tarsus Pharmaceuticals Stock Up 5.1 %

TARS stock opened at $36.35 on Monday. The business has a fifty day moving average price of $31.66 and a 200-day moving average price of $22.46. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.93 and a quick ratio of 6.85. The stock has a market capitalization of $1.24 billion, a P/E ratio of -7.83 and a beta of 1.07. Tarsus Pharmaceuticals, Inc. has a 1-year low of $11.33 and a 1-year high of $40.40.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($1.31) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million during the quarter, compared to the consensus estimate of $4.63 million. During the same period last year, the firm posted ($0.49) EPS. Equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Seshadri Neervannan sold 4,879 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the completion of the sale, the chief operating officer now owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, General Counsel Bryan Wahl sold 4,436 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the transaction, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Seshadri Neervannan sold 4,879 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $149,297.40. Following the completion of the transaction, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,496 shares of company stock valued at $749,578. Company insiders own 11.54% of the company’s stock.

About Tarsus Pharmaceuticals

(Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Articles

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report).

Institutional Ownership by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.